लोड हो रहा है...
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafe...
में बचाया:
| मुख्य लेखकों: | , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Termedia Publishing House
2012
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3400918/ https://ncbi.nlm.nih.gov/pubmed/22852011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2012.29408 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|